Intranasal administration: A potential solution for cross-BBB delivering neurotrophic factors

Histology and Histopathology

Volumn 27, Issue 5, 2012, Pages 537-548

  Zhu, Juehua ^a   Jiang, Yongjun ^a   Xu, Gelin ^a   Liu, Xinfeng ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Intranasal; Neurodegenerative diseases; Neuroprotection; Neurotrophic factors; Stroke

Indexed keywords

NERVE GROWTH FACTOR;

ANIMAL; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL (TOPIC); HUMAN; INTRANASAL DRUG ADMINISTRATION; MALE; METABOLISM; NOSE; REVIEW; TREATMENT FAILURE;

ADMINISTRATION, INTRANASAL; ANIMALS; BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASES; CLINICAL TRIALS AS TOPIC; HUMANS; MALE; NERVE GROWTH FACTORS; NOSE; TREATMENT FAILURE;

ANIMALIA;

EID: 84859339989     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (115)

1. ACTS-Phase-I/II-Study-Group. (1995). A phase I study of recombinant human ciliary neurotrophic factor (rHCNTF) in patients with amyotrophic lateral sclerosis. The ALS CNTF Treatment Study (ACTS) Phase I-II Study Group. Clin. Neuropharmacol. 18, 515-532.
2. Ad-Hoc-Working-Group. (1989). Potential use of nerve growth factor to treat Alzheimer's disease. Science 243, 11.
3. Alcala-Barraza S.R., Lee M.S., Hanson L.R., McDonald A.A., Frey W.H., 2nd and McLoon L.K. (2010). Intranasal delivery of neurotrophic factors BDNF, CNTF, EPO, and NT-4 to the CNS. J. Drug Target 18, 179-190.
4. ALS-CNTF-Treatment-Study-Group. (1996). A double-blind placebocontrolled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. ALS CNTF Treatment Study Group. Neurology 46, 1244-1249.
5. Apfel S.C., Kessler J.A., Adornato B.T., Litchy W.J., Sanders C. and Rask C.A. (1998). Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. NGF Study Group. Neurology 51, 695-702.
6. Apfel S.C., Schwartz S., Adornato B.T., Freeman R., Biton V., Rendell M., Vinik A., Giuliani M., Stevens J.C., Barbano R. and Dyck P.J. (2000). Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: A randomized controlled trial. rhNGF Clinical Investigator Group. JAMA 284, 2215-2221.
7. Ay H., Ay I., Koroshetz W.J. and Finklestein S.P. (1999). Potential usefulness of basic fibroblast growth factor as a treatment for stroke. Cerebrovasc. Dis. 9, 131-135.
8. Banks W.A. (2008). Delivery of peptides to the brain: emphasis on therapeutic development. Biopolymers 90, 589-594.
9. Banks W.A. (2009). Characteristics of compounds that cross the bloodbrain barrier. BMC Neurol. 9 (Suppl 1), S3.
10. Beck H. and Plate K.H. (2009). Angiogenesis after cerebral ischemia. Acta. Neuropathol. 117, 481-496.
11. Beck M., Flachenecker P., Magnus T., Giess R., Reiners K., Toyka K.V. and Naumann M. (2005). Autonomic dysfunction in ALS: a preliminary study on the effects of intrathecal BDNF. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 6, 100-103.
12. Benedict C., Hallschmid M., Hatke A., Schultes B., Fehm H.L., Born J. and Kern W. (2004). Intranasal insulin improves memory in humans. Psychoneuroendocrinology 29, 1326-1334.
13. Bensa S., Hadden R.D., Hahn A., Hughes R.A. and Willison H.J. (2000). Randomized controlled trial of brain-derived neurotrophic factor in Guillain-Barre syndrome: a pilot study. Eur. J. Neurol. 7, 423-426.
14. Bodian D. and Howe H.A. (1940). An experimental study of the role of neurons in the dissemination of polymyelitis virus in the nervous system. Brain 63, 135-162.
15. Bogousslavsky J., Victor S.J., Salinas E.O., Pallay A., Donnan G.A., Fieschi C., Kaste M., Orgogozo J.M., Chamorro A. and Desmet A. (2002). Fiblast (trafermin) in acute stroke: results of the European- Australian phase II/III safety and efficacy trial. Cerebrovasc. Dis. 14, 239-251.
16. Bondier J.R., Michel G., Propper A. and Badot P.M. (2008). Harmful effects of cadmium on olfactory system in mice. Inhal. Toxicol. 20, 1169-1177.
17. Borasio G.D., Robberecht W., Leigh P.N., Emile J., Guiloff R.J., Jerusalem F., Silani V., Vos P.E., Wokke J.H. and Dobbins T. (1998). A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group. Neurology 51, 583-586.
18. Born J., Lange T., Kern W., McGregor G.P., Bickel U. and Fehm H.L. (2002). Sniffing neuropeptides: a transnasal approach to the human brain. Nat. Neurosci. 5, 514-516.
19. Broberg E.K., Peltoniemi J., Nygardas M., Vahlberg T., Roytta M. and Hukkanen V. (2004). Spread and replication of and immune response to gamma134.5-negative herpes simplex virus type 1 vectors in BALB/c mice. J. Virol. 78, 13139-13152.
20. Calabresi P.A., Fields N.S., Maloni H.W., Hanham A., Carlino J., Moore J., Levin M.C., Dhib-Jalbut S., Tranquill L.R., Austin H., McFarland H.F. and Racke M.K. (1998). Phase 1 trial of transforming growth factor beta 2 in chronic progressive MS. Neurology 51, 289-292.
21. Capsoni S., Giannotta S. and Cattaneo A. (2002). Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice. Proc. Natl. Acad. Sci. USA 99, 12432-12437.
22. Chen B., Friedman B., Cheng Q., Tsai P., Schim E., Kleinfeld D. and Lyden P.D. (2009). Severe blood-brain barrier disruption and surrounding tissue injury. Stroke 40, e666-674.
23. Chen X.Q., Fawcett J.R., Rahman Y.E., Ala T.A. and Frey I.W. (1998). Delivery of Nerve Growth Factor to the Brain via the Olfactory Pathway. J. Alzheimers Dis. 1, 35-44.
24. Chen Y., Dalwadi G. and Benson H.A. (2004). Drug delivery across the blood-brain barrier. Curr. Drug Deliv. 1, 361-376.
25. Cheng B. and Mattson M.P. (1992). IGF-I and IGF-II protect cultured hippocampal and septal neurons against calcium-mediated hypoglycemic damage. J. Neurosci. 12, 1558-1566.
26. Clark W.M., Schim J.D., Kasner S.E. and Victor S. (2000). Trafermin in acute ischemic stroke. Results of a phase II/III randomized efficacy study (abstract). Neurology 54.
27. Costantino H.R., Illum L., Brandt G., Johnson P.H. and Quay S.C. (2007). Intranasal delivery: physicochemical and therapeutic aspects. Int. J. Pharm. 337, 1-24.
28. Cuevas P., Carceller F., Ortega S., Zazo M., Nieto I. and Gimenez-Gallego G. (1991). Hypotensive activity of fibroblast growth factor. Science 254, 1208-1210.
29. da Fonseca C.O., Linden R., Futuro D., Gattass C.R. and Quirico-Santos T. (2008a). Ras pathway activation in gliomas: a strategic target for intranasal administration of perillyl alcohol. Arch. Immunol. Ther. Exp. (Warsz) 56, 267-276.
30. da Fonseca C.O., Schwartsmann G., Fischer J., Nagel J., Futuro D., Quirico-Santos T. and Gattass C.R. (2008b). Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas. Surg. Neurol. 70, 259-266; discussion 266-257.
31. de Boer A.G. and Gaillard P.J. (2007). Strategies to improve drug delivery across the blood-brain barrier. Clin. Pharmacokinet. 46, 553-576.
32. De Rosa R., Garcia A.A., Braschi C., Capsoni S., Maffei L., Berardi N. and Cattaneo A. (2005). Intranasal administration of nerve growth factor (NGF) rescues recognition memory deficits in AD11 anti-NGF transgenic mice. Proc. Natl. Acad. Sci. USA 102, 3811-3816.
33. Dhanda D.S., Frey I.W., Leopold D. and Kompella U.B. (2005). Approaches for drug deposition in the human olfactory epithelium. Drug Deliv. Technol. 5, 64-72.
34. Dhuria S.V., Hanson L.R. and Frey W.H. 2nd. (2010). Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J. Pharm. Sci. 99, 1654-1673.
35. Dittrich F., Thoenen H. and Sendtner M. (1994). Ciliary neurotrophic factor: pharmacokinetics and acute-phase response in rat. Ann. Neurol. 35, 151-163.
36. Ditzen B., Schaer M., Gabriel B., Bodenmann G., Ehlert U. and Heinrichs M. (2009). Intranasal oxytocin increases positive communication and reduces cortisol levels during couple conflict. Biol. Psychiatry 65, 728-731.
37. Domes G., Heinrichs M., Glascher J., Buchel C., Braus D.F. and Herpertz S.C. (2007). Oxytocin attenuates amygdala responses to emotional faces regardless of valence. Biol. Psychiatry 62, 1187-1190.
38. Eriksdotter Jonhagen M., Nordberg A., Amberla K., Backman L., Ebendal T., Meyerson B., Olson L., Seiger, Shigeta M., Theodorsson E., Viitanen M., Winblad B. and Wahlund L.O. (1998). Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 9, 246-257.
39. Feifel D., Macdonald K., Nguyen A., Cobb P., Warlan H., Galangue B., Minassian A., Becker O., Cooper J., Perry W., Lefebvre M., Gonzales J. and Hadley A. (2010). Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients. Biol. Psychiatry 68, 678-680.
40. Fletcher L., Kohli S., Sprague S.M., Scranton R.A., Lipton S.A., Parra A., Jimenez D.F. and Digicaylioglu M. (2009). Intranasal delivery of erythropoietin plus insulin-like growth factor-I for acute neuroprotection in stroke. Laboratory investigation. J. Neurosurg. 111, 164-170.
41. Frank J.A., Richert N., Lewis B., Bash C., Howard T., Civil R., Stone R., Eaton J., McFarland H. and Leist T. (2002). A pilot study of recombinant insulin-like growth factor-1 in seven multiple sderosis patients. Mult. Scler. 8, 24-29.
42. Frenkel D. and Solomon B. (2002). Filamentous phage as vectormediated antibody delivery to the brain. Proc. Natl. Acad. Sci. USA 99, 5675-5679.
43. 125I-NGF to the brain via the of lactory route. Drug Deliv. 4, 87-92.
44. Frystyk J., Gronbaek H., Skjaerbaek C. and Flyvbjerg A. (1995). Effect of hyperthyroidism on circulating levels of free and total IGF-I and IGFBPs in rats. Am. J. Physiol. 269, E840-845.
45. Gash D.M., Zhang Z., Ovadia A., Cass W.A., Yi A., Simmerman L., Russell D., Martin D., Lapchak P.A., Collins F., Hoffer B.J. and Gerhardt G.A. (1996). Functional recovery in parkinsonian monkeys treated with GDNF. Nature 380, 252-255.
46. Gill S.S., Patel N.K., Hotton G.R., O'Sullivan K., McCarter R., Bunnage M., Brooks D.J., Svendsen C.N. and Heywood P. (2003). Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med. 9, 589-595.
47. Gluckman P., Klempt N., Guan J., Mallard C., Sirimanne E., Dragunow M., Klempt M., Singh K., Williams C. and Nikolics K. (1992). A role for IGF-1 in the rescue of CNS neurons following hypoxic-ischemic injury. Biochem. Biophys. Res. Commun. 182, 593-599.
48. Gotoh O., Asano T., Koide T. and Takakura K. (1985). Ischemic brain edema following occlusion of the middle cerebral artery in the rat. I: The time courses of the brain water, sodium and potassium contents and blood-brain barrier permeability to 125I-albumin. Stroke 16, 101-109.
49. Graff C.L. and Pollack G.M. (2003). P-Glycoprotein attenuates brain uptake of substrates after nasal instillation. Pharm. Res. 20, 1225-1230.
50. Guan J., Williams C., Gunning M., Mallard C. and Gluckman P. (1993). The effects of IGF-1 treatment after hypoxic-ischemic brain injury in adult rats. J. Cereb. Blood Flow Metab. 13, 609-616.
51. Guastella A.J., Howard A.L., Dadds M.R., Mitchell P. and Carson D.S. (2009). A randomized controlled trial of intranasal oxytocin as an adjunct to exposure therapy for social anxiety disorder. Psychoneuroendocrinology 34, 917-923.
52. Han I.K., Kim M.Y., Byun H.M., Hwang T.S., Kim J.M., Hwang K.W., Park T.G., Jung W.W., Chun T., Jeong G.J. and Oh Y.K. (2007). Enhanced brain targeting efficiency of intranasally administered plasmid DNA: an alternative route for brain gene therapy. J. Mol. Med. (Berl) 85, 75-83.
53. Hanson L.R. and Frey W.H. 2nd. (2007). Strategies for intranasal delivery of therapeutics for the prevention and treatment of neuroAIDS. J. Neuroimmune Pharmacol. 2, 81-86.
54. Hashizume R., Ozawa T., Gryaznov S.M., Bollen A.W., Lamborn K.R., Frey W.H. 2nd and Deen D.F. (2008). New therapeutic approach for brain tumors: Intranasal delivery of telomerase inhibitor GRN163. Neuro. Oncol. 10, 112-120.
55. Hefti F. (1997). Pharmacology of neurotrophic factors. Annu. Rev. Pharmacol. Toxicol. 37, 239-267.
56. Hemmer B., Cepok S., Zhou D. and Sommer N. (2004). Multiple sclerosis -- a coordinated immune attack across the blood brain barrier. Curr. Neurovasc. Res. 1, 141-150.
57. Henkin R.I. (2010). Intranasal insulin: from nose to brain. Nutrition 26, 624-633.
58. Horner P.J. and Gage F.H. (2000). Regenerating the damaged central nervous system. Nature 407, 963-970.
59. Hurlemann R., Patin A., Onur O.A., Cohen M.X., Baumgartner T., Metzler S., Dziobek I., Gallinat J., Wagner M., Maier W. and Kendrick K.M. (2010). Oxytocin enhances amygdala-dependent, socially reinforced learning and emotional empathy in humans. J. Neurosci. 30, 4999-5007.
60. Iadecola C. (2010). The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta. Neuropathol. 120, 287-296.
61. Illum L. (2000). Transport of drugs from the nasal cavity to the central nervous system. Eur. J. Pharm. Sci. 11, 1-18.
62. Illum L. (2004). Is nose-to-brain transport of drugs in man a reality? J. Pharm. Pharmacol. 56, 3-17.
63. Jiang Y., Wei N., Lu T., Zhu J., Xu G. and Liu X. (2011a). Intranasal brain-derived neurotrophic factor protects brain from ischemic insult via modulating local inflammation in rats. Neuroscience 172, 398-405.
64. Jiang Y., Zhu J., Xu G. and Liu X. (2011b). Intranasal delivery of stem cells to the brain. Expert Opin. Drug Deliv. 8, 623-632.
65. Kastin A.J., Pan W., Maness L.M. and Banks W.A. (1999). Peptides crossing the blood-brain barrier: some unusual observations. Brain Res. 848, 96-100.
66. Knusel B., Michel P.P., Schwaber J.S. and Hefti F. (1990). Selective and nonselective stimulation of central cholinergic and dopaminergic development in vitro by nerve growth factor, basic fibroblast growth factor, epidermal growth factor, insulin and the insulin-like growth factors I and II. J. Neurosci. 10, 558-570.
67. Kooijman R., Sarre S., Michotte Y. and De Keyser J. (2009). Insulin-like growth factor I: a potential neuroprotective compound for the treatment of acute ischemic stroke? Stroke 40, e83-88.
68. Kortekaas R., Leenders K.L., van Oostrom J.C., Vaalburg W., Bart J., Willemsen A.T. and Hendrikse N.H. (2005). Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann. Neurol. 57, 176-179.
69. Kosfeld M., Heinrichs M., Zak P.J., Fischbacher U. and Fehr E. (2005). Oxytocin increases trust in humans. Nature 435, 673-676.
70. Lai E.C., Felice K.J., Festoff B.W., Gawel M.J., Gelinas D.F., Kratz R., Murphy M.F., Natter H.M., Norris F.H. and Rudnicki S.A. (1997). Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group. Neurology 49, 1621-1630.
71. Lang A.E., Gill S., Patel N.K., Lozano A., Nutt J.G., Penn R., Brooks D.J., Hotton G., Moro E., Heywood P., Brodsky M.A., Burchiel K., Kelly P., Dalvi A., Scott B., Stacy M., Turner D., Wooten V.G., Elias W.J., Laws E.R., Dhawan V., Stoessl A.J., Matcham J., Coffey R.J. and Traub M. (2006). Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol. 59, 459-466.
72. Lin L.F., Doherty D.H., Lile J.D., Bektesh S. and Collins F. (1993). GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260, 1130-1132.
73. Lin S., Fan L.W., Rhodes P.G. and Cai Z. (2009). Intranasal administration of IGF-1 attenuates hypoxic-ischemic brain injury in neonatal rats. Exp. Neurol. 217, 361-370.
74. Liu X.F., Fawcett J.R., Thorne R.G., DeFor T.A. and Frey W.H. 2nd. (2001). Intranasal administration of insulin-like growth factor-I bypasses the blood-brain barrier and protects against focal cerebral ischemic damage. J. Neurol. Sci. 187, 91-97.
75. Ma Y.P., Ma M.M., Ge S., Guo R.B., Zhang H.J., Frey W.H. 2nd, Xu G.L. and Liu X.F. (2007). Intranasally delivered TGF-beta1 enters brain and regulates gene expressions of its receptors in rats. Brain Res. Bull. 74, 271-277.
76. Ma M., Ma Y., Yi X., Guo R., Zhu W., Fan X., Xu G., Frey W.H. 2nd and Liu X. (2008a). Intranasal delivery of transforming growth factorbeta1 in mice after stroke reduces infarct volume and increases neurogenesis in the subventricular zone. BMC Neurosci. 9, 117.
77. Ma Y.P., Ma M.M., Cheng S.M., Ma H.H., Yi X.M., Xu G.L. and Liu X.F. (2008b). Intranasal bFGF-induced progenitor cell proliferation and neuroprotection after transient focal cerebral ischemia. Neurosci. Lett. 437, 93-97.
78. McArthur J.C., Yiannoutsos C., Simpson D.M., Adornato B.T., Singer E.J., Hollander H., Marra C., Rubin M., Cohen B.A., Tucker T., Navia B.A., Schifitto G., Katzenstein D., Rask C., Zaborski L., Smith M.E., Shriver S., Millar L., Clifford D.B. and Karalnik I.J. (2000). A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. AIDS Clinical Trials Group Team 291. Neurology 54, 1080-1088.
79. Menzies S.A., Betz A.L. and Hoff J.T. (1993). Contributions of ions and albumin to the formation and resolution of ischemic brain edema. J. Neurosurg. 78, 257-266.
80. Merkus F.W. and van den Berg M.P. (2007). Can nasal drug delivery bypass the blood-brain barrier?: questioning the direct transport theory. Drugs R. D. 8, 133-144.
81. Merkus P., Guchelaar H.J., Bosch D.A. and Merkus F.W. (2003). Direct access of drugs to the human brain after intranasal drug administration? Neurology 60, 1669-1671.
82. Miller R.G., Petajan J.H., Bryan W.W., Armon C., Barohn R.J., Goodpasture J.C., Hoagland R.J., Parry G.J., Ross M.A. and Stromatt S.C. (1996). A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group. Ann. Neurol. 39, 256-260.
83. Miyamoto M., Natsume H., Satoh I., Ohtake K., Yamaguchi M., Kobayashi D., Sugibayashi K. and Morimoto Y. (2001). Effect of poly-L-arginine on the nasal absorption of FITC-dextran of different molecular weights and recombinant human granulocyte colonystimulating factor (rhG-CSF) in rats. Int. J. Pharm. 226, 127-138.
84. Nagano I., Shiote M., Murakami T., Kamada H., Hamakawa Y., Matsubara E., Yokoyama M., Moritaz K., Shoji M. and Abe K. (2005). Beneficial effects of intrathecal IGF-1 administration in patients with amyotrophic lateral sclerosis. Neurol. Res. 27, 768-772.
85. Nutt J.G., Burchiel K.J., Comella C.L., Jankovic J., Lang A.E., Laws E.R. Jr., Lozano A.M., Penn R.D., Simpson R.K. Jr., Stacy M. and Wooten G.F. (2003). Randomized, double-blind trial of glial cell linederived neurotrophic factor (GDNF) in PD. Neurology 60, 69-73.
86. Ochs G., Penn R.D., York M., Giess R., Beck M., Tonn J., Haigh J., Malta E., Traub M., Sendtner M. and Toyka K.V. (2000). A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 1, 201-206.
87. Olson L., Nordberg A., von Holst H., Backman L., Ebendal T., Alafuzoff I., Amberla K., Hartvig P., Herlitz A., Lilja A., Lundqvist H., Langstrom B., Meyerson B., Persson A., Viitanen M., Windblad B. and Seiger A. (1992). Nerve growth factor affects 11C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient (case report). J. Neural Transm. Park. Dis. Dement. Sect. 4, 79-95.
88. Pan W., Banks W.A., Fasold M.B., Bluth J. and Kastin A.J. (1998). Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 37, 1553-1561.
89. Pardridge W.M. (2005). The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2, 3-14.
90. Patel N.K., Bunnage M., Plaha P., Svendsen C.N., Heywood P. and Gill S.S. (2005). Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. Ann. Neurol. 57, 298-302.
91. Penn R.D., Kroin J.S., York M.M. and Cedarbaum J.M. (1997). Intrathecal ciliary neurotrophic factor delivery for treatment of amyotrophic lateral sclerosis (phase I trial). Neurosurgery 40, 94-99; discussion 99-100.
92. Persidsky Y., Ramirez S.H., Haorah J. and Kanmogne G.D. (2006). Blood-brain barrier: structural components and function under physiologic and pathologic conditions. J. Neuroimmune Pharmacol. 1, 223-236.
93. Reger M.A., Watson G.S., Frey W.H. 2nd, Baker L.D., Cholerton B., Keeling M.L., Belongia D.A., Fishel M.A., Plymate S.R., Schellenberg G.D., Cherrier M.M. and Craft S. (2006). Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol. Aging 27, 451-458.
94. Reger M.A., Watson G.S., Green P.S., Wilkinson C.W., Baker L.D., Cholerton B., Fishel M.A., Plymate S.R., Breitner J.C., DeGroodt W., Mehta P. and Craft S. (2008). Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 70, 440-448.
95. Savaskan E., Ehrhardt R., Schulz A., Walter M. and Schachinger H. (2008). Post-learning intranasal oxytocin modulates human memory for facial identity. Psychoneuroendocrinology 33, 368-374.
96. Schifitto G., Yiannoutsos C., Simpson D.M., Adornato B.T., Singer E.J., Hollander H., Marra C.M., Rubin M., Cohen B.A., Tucker T., Koralnik I.J., Katzenstein D., Haidich B., Smith M.E., Shriver S., Millar L., Clifford D.B. and McArthur J.C. (2001). Long-term treatment with recombinant nerve growth factor for HIV-associated sensory neuropathy. Neurology 57, 1313-1316.
97. Semkova I. and Krieglstein J. (1999). Neuroprotection mediated via neurotrophic factors and induction of neurotrophic factors. Brain Res. Brain Res. Rev. 30, 176-188.
98. Sendtner M., Schmalbruch H., Stockli K.A., Carroll P., Kreutzberg G.W. and Thoenen H. (1992). Ciliary neurotrophic factor prevents degeneration of motor neurons in mouse mutant progressive motor neuronopathy. Nature 358, 502-504.
99. Slevin J.T., Gerhardt G.A., Smith C.D., Gash D.M., Kryscio R. and Young B. (2005). Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J. Neurosurg. 102, 216-222.
100. Slevin J.T., Gash D.M., Smith C.D., Gerhardt G.A., Kryscio R., Chebrolu H., Walton A., Wagner R. and Young A.B. (2007). Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal. J. Neurosurg. 106, 614-620.
101. Sorenson E.J., Windbank A.J., Mandrekar J.N., Bamlet W.R., Appel S.H., Armon C., Barkhaus P.E., Bosch P., Boylan K., David W.S., Feldman E., Glass J., Gutmann L., Katz J., King W., Luciano C.A., McCluskey L.F., Nash S., Newman D.S., Pascuzzi R.M., Pioro E., Sams L.J., Scelsa S., Simpson E.P., Subramony S.H., Tiryaki E. and Thornton C.A. (2008). Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology 71, 1770-1775.
102. The-BDNF-Study-Group. (1999). A controlled trial of recombinant methionyl human BDNF in ALS: The BDNF Study Group (Phase III). Neurology 52, 1427-1433.
103. The-Fibroblast-Safety-Study-Group. (1998). Clinical safety trial of intravenous basic fibroblast growth factor (bFGF, FIBLAST) in acute stroke (abstract). Stroke 29, 287.
104. Thorne R.G. and Frey W.H. 2nd. (2001). Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations. Clin. Pharmacokinet. 40, 907-946.
105. Thorne R.G., Pronk G.J., Padmanabhan V. and Frey W.H. 2nd. (2004). Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 127, 481-496.
106. Thorne R.G., Hanson L.R., Ross T.M., Tung D. and Frey W.H. 2nd. (2008). Delivery of interferon-beta to the monkey nervous system following intranasal administration. Neuroscience 152, 785-797.
107. Tsikunov S.G. and Belokoskova S.G. (2007). Psychophysiological analysis of the influence of vasopressin on speech in patients with post-stroke aphasias. Span J. Psychol. 10, 178-188.
108. Vyas T.K., Shahiwala A., Marathe S. and Misra A. (2005). Intranasal drug delivery for brain targeting. Curr. Drug Deliv. 2, 165-175.
109. Wang Z.L., Cheng S.M., Ma M.M., Ma Y.P., Yang J.P., Xu G.L. and Liu X.F. (2008). Intranasally delivered bFGF enhances neurogenesis in adult rats following cerebral ischemia. Neurosci. Lett. 446, 30-35.
110. Wellmer A., Misra V.P., Sharief M.K., Kopelman P.G. and Anand P. (2001). A double-blind placebo-controlled clinical trial of recombinant human brain-derived neurotrophic factor (rhBDNF) in diabetic polyneuropathy. J. Peripher. Nerv. Syst. 6, 204-210.
111. Will B. and Hefti F. (1985). Behavioural and neurochemical effects of chronic intraventricular injections of nerve growth factor in adult rats with fimbria lesions. Behav. Brain Res. 17, 17-24.
112. Wu H., Hu K. and Jiang X. (2008). From nose to brain: understanding transport capacity and transport rate of drugs. Expert Opin. Drug Deliv. 5, 1159-1168.
113. Yang J.P., Liu H.J., Cheng S.M., Wang Z.L., Cheng X., Yu H.X. and Liu X.F. (2009). Direct transport of VEGF from the nasal cavity to brain. Neurosci. Lett. 449, 108-111.
114. Yang J.P., Liu H.J. and Liu X.F. (2010). VEGF promotes angiogenesis and functional recovery in stroke rats. J. Invest. Surg. 23, 149-155.
115. Zhang Y. and Pardridge W.M. (2001). Neuroprotection in transient focal brain ischemia after delayed intravenous administration of brainderived neurotrophic factor conjugated to a blood-brain barrier drug targeting system (editorial comment). Stroke 32, 1378-1384.